alnylam
The Associate Director, Downstream, Emerging Modalities will lead technical development of purification processes for novel antibody and conjugate therapeutics, guiding programs from preclinical through Phase I and supporting regulatory submissions. This on‑site role in Cambridge, MA collaborates with cross‑functional teams and external partners to establish scalable, robust downstream strategies for emerging modalities.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
10% below the average for this role
Scientist I/II
MacroGenics
Sr. Associate Scientist, R&D Chemistry, Peptidomimetic Purification
Regeneron Pharmaceuticals
Intern, Downstream Production
Hummingbirdbio
Senior Scientist, CMC Downstream Process Development
Neurocrine Biosciences
Scientist, Viral Vector Process Development (Downstream)
AstraZeneca
Senior Scientist I (Downstream Process Development)
GovernmentJobs